Drug approvals and emerging research highlighted the news in the HIV space this past year.
Drug approvals and emerging research highlighted the news in the HIV space this past year. Check out some of our top HIV coverage of 2018:
10. Modified Antiviral Drug Could Cure HIV
Altering the chemical structure of an antiviral drug may help it penetrate HIV viral reservoirs and could expedite the public health goal of curing HIV.
9. HIV Drug Gets Final FDA Approval
The FDA announced that it granted final approval for an Abbreviated New Drug Application for tenofovir disoproxil fumarate 300-mg tablets for the treatment of HIV-1 infection in adults and pediatric patients ages 12 years and older.
8. Reducing HIV-Related Stigma Among Providers Improves Care
Provider-centric stigma reduction interventions can help reduce stigmatizing behaviors towards patients with HIV and potentially improve care.
7. Could a Super Receptor Be the Answer to Eradicating HIV?
Researchers have discovered a receptor on immune cells that may be the answer to eradicating HIV.
6. Use of Truvada for HIV Prevention Associated with Decline in New US Diagnoses
Use of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) for HIV prevention was associated with a significant decline in new diagnoses across the United States, according to data presented at the International AIDS Conference.
5. New Data Support Switch to Single-Tablet Darunavir-Based Regimen for HIV Treatment
New research demonstrates continued virologic control in patients with HIV-1 following a switch to Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg [D/C/F/TAF]) regardless of prior treatment regimen,
4. Investigational Gene Therapy Produced 2 Year Immunity Against HIV
A study published by PLOS Pathogens suggests that gene therapy may benefit patients with HIV who currently have to take daily antiretroviral therapy (ART) to prevent the disease from progressing to AIDS and associated adverse events.
3. Two New HIV Treatments Gain FDA Approvals
Officials with the FDA approved Merck’s doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) tablet and doravirine (Pifeltro) for the treatment of HIV-1.
2. Closing HIV Treatment Gaps Essential to Ending Epidemic
Viral suppression rates among people living with HIV (PLWH) have drastically improved across the United States, but disparities among younger and black PLWH need to be addressed.
1. FDA OKs First Darunavir-Based Single-Tablet Treatment Regimen for HIV
Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) is the first and only complete darunavir-based single tablet regimen (STR) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults.